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ABSTRACT 
Predicting which peptides can elicit a T cell response (i.e. are 
immunogenic) is of great importance for many immunological 
studies. While it is clear that MHC binding is a necessary 
requirement for peptide immunogenicity, other variables exist that 
are incompletely understood.  
In this study we examined the hypothesis that conservation of a 
peptide in bacteria that are part of the healthy human microbiome 
leads to a reduced level of immunogenicity due to tolerization of 
T cells to the commensal bacteria. This was done by comparing 
experimentally characterized T cell epitope recognition data from 
the Immune Epitope Database with their conservation in the 
human microbiome. Indeed, we did see a lower immunogenicity 
for conserved peptides conserved. While many aspects how this 
conservation comparison is done require further optimization, this 
is a first step towards a better understanding T cell recognition of 
peptides in bacterial pathogens is influenced by their conservation 
in commensal bacteria. If the further work proves that this 
approach is successful, the degree of overlap of a peptide with the 
human proteome or microbiome could be added to the arsenal of 
tools available to assess peptide immunogenicity. 
 
Categories and Subject Descriptors 
J.3 [Life and Medical Sciences]: biology and genetics, health. 
General Terms 
Experimentation. Theory. Documentation.  
Keywords 
Immune epitope database, human microbiome, epitopes, sequence 
conservation, immunogenicity 
 
1. INTRODUCTION / BACKGROUND 
Several methods are available that can accurately predict binding 
of peptides to MHCI and MHCII molecules (Karosiene et al., 
2012; Kim et al., 2012; Nielsen et al., 2008; Peters et al., 2006; 
Wang et al., 2008). Binding to an MHC molecule is an essential 
though not sufficient criterion for a peptide to be recognized by T 
cells as an immune target. Many aspects of why certain peptides 
are targeted by T cells why some do not remain unknown. 
The immune Epitope Database (IEDB) (Vita et al., 2010) contains 
a catalog of experimentally characterized B and T cell epitopes 
with both positive and negative results. By mining these data, 
comparing which peptides create an immune response and which 
do not, we can learn more about the immune recognition patterns. 
In this study, we examined the hypothesis that conservation of 
peptides from bacterial pathogens in the human proteome and/or 
the human microbiome impacts their ability to activate a T cell 
mediated immune response. Tolerance against peptides conserved 
in the human proteome is expected to result from negative 
selection against T cells reactive with self-peptides during T cell 
maturation while tolerance to peptides found in commensal 
microbacteria has been postulated to be the result of peripheral 
tolerance induced by regulatory T cells. However, the extent to 
which these mechanisms impact recognition of peptides from 
bacterial pathogens has not been systematically examined. Here 
we examined this hypothesis by correlating human immune 
recognition of epitopes available in the IEDB with sequence 
conservation data from the Human Microbiome Project (HMP). In 
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the process, we tackle the problem of how to quantify the degree 
of immunogenicity of a peptide given aggregate data from 
multiple studies. The result of this work in progress so far is that 
there is a significant impact of peptide conservation in the human 
microbiome on the immune reactivity of a peptide.  
 
2. MATERIAL & METHODS  
2.1 Data 
2.1.1 Peptides tested for T cell immune recognition 
The peptides used in this study have been queried from the IEDB 
(Vita et al., 2010). Peptides from bacteria for which responses 
were measured in humans were included in the study. We 
restricted the analysis to include only peptides tested for MHC 
class II restricted / CD4+ T cell responses. The exact query 
parameters were: Source Organism: Bacterium (id: 2, Synonym: 
bacteria), Immune Recognition Context: T Cell Response, Host 
Organism: Homo sapiens, MHC Class: positive assays were 
MHC-II restricted and negative assays were MHC-II restricted or 
restriction undefined. The obtained peptides were all restricted to 
be between 12 and 25 amino acids in length. This peptide set 
includes 24,490 unique peptides and contains information about 
source organism as well as how many times it was tested positive 
and/or negative.   
2.1.2 The human proteome 
To compare the IEDB peptides to the human proteome,  a 
reference proteome dataset was downloaded from 
www.uniprot.org (Consortium, 2014) in fasta format including all 
proteins recognized as part of a reference proteome, including 
both canonical sequence and all isoforms, as well as both 
reviewed and unreviewed  proteins.   
2.1.3 The human microbiome 
To compare the IEDB peptides to commensal bacteria, proteins 
encoded in annotated reference genomes from the Human 
Microbiome Project (HMP) (Peterson et al., 2009) were used. 
Protein sequences were retrieved in fasta format from the HMP 
Data Analysis and Coordination Center 
(http://www.hmpdacc.org/).  Either the entire set of proteins from 
reference genomes were used or those limited to the 6 most highly 
represented body sites: airways, blood, gastrointestinal tract, oral, 
skin, and urogenital tract. 
 
2.2 Methods 
2.2.1 Immunogenicity score 
The same peptide is often tested in multiple studies and 
individuals. It is not expected that even the most immunogenic 
peptide will be positive in every individual due to genetic 
difference (most of all in HLA composition) and differences in 
exposure history. In order to quantify immune reactivity, for each 
peptide a count was made of number of subjects tested, N, and 
number of subjects responded, R. For peptides submitted to the 
IEDB where no information exist on number of responded and 
tested donors the following values were assigned; R = 1, N = 1 if 
the peptide was noted as positive and R = 0, N = 1 if noted as 
negative.  
A response frequency was then calculated as R/N. However, using 
this ratio a peptide found positive in 1/1 donors would be 
considered more immunogenic than a peptide responding in an 
unheard of 99/100 donors. In order to favor data from larger 
sample sizes, a correction of the response frequency was made. As 
we have a binomial distribution, the lower 95% bound of binomial 
confidence interval was chosen as the corrected response 
frequency.  
The cumulative binomial distribution function is as following:  
 
(1)   
 
where k is number of successes, n is number of donors tested and 
p is probability of success. F is the probability of getting k or less 
success. We wanted to solve for p, when F = 0.95. F signifies a 95 
% probability of getting at least k responded out of n tested, with 
p probability of success. If, for example, 5 responded out of 10 
donors tested, the uncorrected response frequency (probability of 
success) is p = 0.5. When asking for what probability p would we 
observe at most 5 donors responding with 95% confidence (F = 
0.95) we get p = 0.22 which is then the adjusted response 
frequency. If in contrast only 2 donors were tested and one was 
positive, the adjusted response frequency is 0.02. 
As the function in equation (1) is a sum function, it is not easily 
solved analytically. Therefore different approximations have been 
made to make confidence interval for binomial distributions. 
Among others the Wilson score interval, which works for 
relatively small samples and/or extreme probabilities. The Wilson 
score interval is defined as: 
 
(2)  
 
 
n being number of donors tested,  is the number of responded 
divided by number of tested (i.e. the uncorrected response 
frequency) and z being 1-½𝛂 of a standard normal distribution. In 
our case 𝛂 = 0.95 because we want a 95 % confidence interval, 
and z is correspondingly 1.96. For peptides with higher numbers 
of responded and tested donors (N>50) the approximation above 
agrees with numeric solutions to equation (1) with less than 1% 
difference, but when we go to the extreme cases, where a normal 
distribution no longer can be assumed, the Wilson score interval 
overestimates the positivity. To avoid this issue a matrix with p 
values was made. To have a starting point the p value was first set 
to number of responded divided by number of tested donors (R/N) 
and adjusted until F = 0.95. This was done for all cases of 0 ≤ R ≤ 
50 and 1 ≤ N ≤ 50. For instances with N > 50, equation (2) was 
used to calculate the adjusted response frequency. We use the 
corrected response frequency value as a measure for the peptide 
immunogenicity and refer to it as the peptide immunogenicity 
score. 
2.2.2 Mapping epitopes 
To compare the IEDB peptides to the human- and human 
microbiome proteomes, lists were made containing all unique 
peptides from the proteomes, to which the IEDB peptides were 
then mapped.  
Oseroff et al. (2010) found that peptide isoforms of length 15 with 
1 or 2 mismatches in most cases showed the same T cell reactivity 
in a given donor. Therefore, in our study peptides with up to 2 
mismatches were allowed for 15mer peptides and considered to be 
‘mapping’ to each other. This number was adjusted for the 
peptides of other lengths so that 2/15 mismatches were allowed 
π
F(k;n, p) =Pr(X ≤ k) = ni
"
#
$
%
&
' pi (1− p)n−i
i=0
k
∑
1
1+ 1n z
2
π +
1
2n z
2 ± z 1n π (1−π )+
1
4n2 z
2"
#
$
%
&
'
ACM-BCB 2014 740
per amino acid in the peptide. No gaps were allowed. The 
mapping was done against 8 different lists; one list containing the 
human proteome, one containing the complete set of the human 
microbiome, and one for each of the six body sites chosen for 
closer analysis. The mapping was done using a custom script, 
which first generates all unique peptides in the epitope dataset and 
our lists, respectively, and then compare the two lists.   
 
2.2.3 Statistical evaluation of results 
For testing the significance of the difference in average positivity 
between body sites, a one-way ANOVA test was used.  
For testing significance of the difference in average positivity 
between peptides mapping and not mapping to the human 
proteome and the complete human microbiome, student’s t-test 
was used. 
For the mapping to the complete human microbiome the peptides 
were also characterized as either positive or negative based on a 
cutoff in the immunogenicity score empirically found to be 
optimal at 0.04. For this a Fisher’s exact test was used to test the 
significance of the distribution of positive and negative peptides 
mapping and not mapping.  
 
3. RESULTS 
3.1 Assembly of epitope dataset  
The dataset assembled from the IEDB consists of a total of 24,490 
peptides with unique sequences of which the main part originates 
from Mycobacterium tuberculosis. Table 1 shows the distribution 
of species in the dataset. Note that the total number of peptides in 
column 2 is higher than the number of peptides with unique 
sequences from the IEDB because 49 peptides are listed as 
originating from two different species in the IEDB and 2 peptides 
are listed for 4 species.  
 
Table 1. The origin of the different peptides in the dataset. 
First column indicates the species, second column indicates how 
many peptides originate from the given species in the IEDB, and 
the third column shows the percentage of the total number of 
peptides.  
Species from IEDB Number of 
peptides 
% of 
peptides 
Mycobacterium tuberculosis 21039 85.63 
Clostridium tetani 844 3.43 
Brucella melitensis 500 2.03 
Burkholderia pseudomallei 324 1.32 
Mycobacterium leprae 287 1.17 
Bacillus licheniformis 245 1.00 
Leptospira interrogans 219 0.89 
Bacillus anthracis 178 0.72 
Mycobacterium bovis 149 0.61 
Helicobacter pylori 102 0.42 
Streptococcus pyogenes 90 0.37 
Bacillus amyloliquefaciens 89 0.36 
Bacillus lentus 86 0.35 
Corynebacterium diphtheriae 54 0.22 
Borrelia burgdorferi 44 0.18 
Francisella tularensis 37 0.15 
Streptococcus mutans 33 0.13 
Bordetella pertussis 33 0.13 
Pseudomonas aeruginosa 31 0.13 
Neisseria meningitidis 26 0.11 
Staphylococcus aureus 18 0.07 
Escherichia coli 17 0.07 
Haemophilus influenzae 16 0.07 
Chlamydia trachomatis 15 0.06 
Listeria monocytogenes 13 0.05 
Others 82 0.33 
Total: 24,571 100.0 
 
Table 2. Breakdown of peptides mapping to proteomes. The 
table gives an overview of the total number of peptides in the 
dataset, how many of these peptides map to different lists, and 
how large the different lists are.  
 Number of 
peptides 
Number of 
proteomes 
in list 
Total records from IEDB 36,619 - 
Unique peptides from IEDB 24,490 - 
Mapping to the human proteome 45 1 
Mapping to the complete human 
microbiome 
9,129 1,097 
Mapping to airways 1,888 50 
Mapping to blood 289 42 
Mapping to gastrointestinal tract 1,454 354 
Mapping to oral 1,959 193 
Mapping to skin 3,036 114 
Mapping to urogenital tract 8,192* 128 
* The high number of peptides mapping to the urogenital tract, compared 
to the other body sites, are due to one Mycobacterium present in that list 
and the abundance of Mycobacterium tuberculosis peptides in our epitope 
dataset. 
 
3.2 Mapping to the human proteome 
Given our mapping criteria, only 45 bacterial peptides with 
immune recognition information mapped to the human proteome. 
Figure 1 shows the distribution of the peptides. When calculating 
their immunogenicity score, the mean of peptides that mapped to 
the human proteome was 0.0233 and the mean of peptides not 
mapping was 0.0082. While we had expected a lower 
immunogenicity of peptides mapping to the human proteome, 
given the low number of peptides mapping, this dataset is simply 
not powerful enough to support or refute this hypothesis.   
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Figure 1. Comparing the distribution of immunogenicity 
scores for peptides mapping to the human proteome vs. those 
that do not. The plot shows the distribution of the peptides based 
on their immunogenicity score (positivity fractions) for the 
mapping to the human proteome. The peptides were divided into 
bins based on their positivity (immunogenicity score). The 
fraction of peptides mapping to the human proteome in each bin 
are indicated in green while those that did not map to the human 
proteome are indicated in blue.  
 
3.3 Mapping to the human microbiome 
Next, we mapped the bacterial peptides with immune recognition 
information to the human microbiome and found a much larger 
number of mapping peptides, namely 9,129. The distribution of 
the immunogenicity scores is shown in Figure 2. The average 
immunogenicity score of peptides that mapped to the human 
microbiome was 0.0073, while the peptides that did not map had a 
higher mean score of 0.0093. This difference is statistically 
significant (p-value = 0.0022, two-sided t-test). This suggests that 
bacterial peptides that are found in commensal bacteria present in 
the human microbiome have an overall lower ability to trigger an 
immune response.  
 
3.4 Differential analysis of microbiota in 
separate body sites 
Finally, we considered peptides mapping to microbial organisms 
found in different body sites separately. We considered the 6 body 
sites for which the largest number of reference genomes was 
available in the HMP project. Figure 3 depicts the number of 
peptides mapping. The p-value from the one-way ANOVA test, 
testing whether the average immunogenicity score for peptides 
mapping to each of the six body sites are different, is 4.182*10-14 
which is highly significant on a 95 % level of significance. In the 
post hoc analysis examining which body sites contribute most to 
this difference, the standard error was calculated to be 0.0034, this 
was plotted in figure 3 and thus it can be seen that peptides 
mapping to microbiota found in the skin and urogenital tract have 
a significantly lower immunogenicity from those mapping to 
airways, blood, and oral, and also that peptides mapping to 
microbiota in the gastrointestinal tract have a significantly lower 
immunogenicity from blood and oral. 
 
 
Figure 2. Comparing the distribution of immunogenicity 
scores for peptides mapping to the human microbiome vs. 
those that do not. As in Figure 2, the distribution of peptides 
mapping are shown in green while those that do not map are 
shown in blue.  
 
Figure 3. Immunogenicity of peptides mapping to 
microbiomes found in different body sites. The plot shows the 
differences in average immunogenicity score between the 6 
different body sites. The number on top of each bar is the number 
of unique peptides mapping to that body site and the average 
positivity is calculated based on these. The error bars show the 
standard error of the differences between the groups. 
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4. DISCUSSION / CONCLUSION 
The results of our work in progress are promising. Our starting 
hypothesis was that conservation of a peptide in the healthy 
human microbiome would lead to a reduced level of immune 
recognition due to tolerization to the commensal bacteria. This is 
supported by our results. We do see a lower average positivity for 
the mapping peptides than for the non-mapping peptides. This 
supported our theory and prompted us to investigate further.  
Therefore we looked into the different body sites. It is known that 
the commensal bacteria in the gastrointestinal tract interacts 
closely with the immune system (Kamada et al., 2013) and so we 
would expect it to be different from that of other sites. Our 
analysis shows that it is significantly lower than blood and oral, 
but higher (although not significantly) than skin and urogenital 
tract. The skin acts a physical barrier and therefore one would not 
expect a close interaction with the immune system and hence not 
a high tolerization.  
There are several caveats to our current analysis. Most 
importantly, the epitope dataset used in this study is largely 
dominated by the peptides originating from Mycobacterium 
tuberculosis (TB), which constitutes 85.63 % of the peptides (See 
table 1). This is mainly due to a whole genome study of the 
epitopes in Mycobacterium tuberculosis done by (Lindestam 
Arlehamn et al., 2013). 
Having tested the entire genome for T cell reaction creates a 
dataset that is very comprehensive but hard to compare other 
organisms such as Clostridium tetani, where the peptides 
exclusively originates from the tetanus toxin, none of which are 
mapping to neither the human proteome nor the human 
microbiome. Since the entire TB genome were studied the 
peptides contain a larger proportion of negative peptides 
compared to other studies where only peptides assumed to have a 
T cell response were tested. It could influence the results that the 
average positivity of the TB peptides is lower than the rest of the 
dataset. Therefore the next step in this study is to analyze the TB 
data and the rest of dataset separately.  
The results for the mapping of the human proteome are non-
significant and furthermore the results actually show the opposite 
of what we would expect. It is known that there is a negative 
selection of self-antigens and so we expected to see that reflected 
in the results. However out of 24,490 peptides there are only 45 
mapping peptides, which is too low to make strong conclusions. 
One approach we will test going forward is the use of multiple 
human proteomes to represent the inter-individual variability of 
what is considered a self-antigen, which might pick up additional 
mapping peptides. 
Overall, we believe our analysis is a first step towards a better 
understanding how conservation of peptides in commensal 
bacteria shapes their recognition when present in bacterial 
pathogens. Given the inherent limitations when using public data 
generated for a completely different purpose than what we are 
examining in our study, our plan to address the caveats above is to 
formulate a testable hypothesis, and design a dedicated 
experiment to test it. If successful, the degree of overlap of a 
peptide with the human proteome or microbiome could be added 
to the arsenal of tools available to assess peptide immunogenicity, 
which have practical applications in peptide vaccine design and 
de-immunizing of protein therapeutics.   
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